Last reviewed · How we verify

Estradiol 0.01% Vag Cream — Competitive Intelligence Brief

Estradiol 0.01% Vag Cream (Estradiol 0.01% Vag Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor agonist. Area: Gynecology / Women's Health.

marketed Estrogen receptor agonist Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Gynecology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Estradiol 0.01% Vag Cream (Estradiol 0.01% Vag Cream) — TriHealth Inc.. Estradiol binds to estrogen receptors in vaginal tissue to restore local estrogen levels and alleviate symptoms of vaginal atrophy and genitourinary syndrome of menopause.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Estradiol 0.01% Vag Cream TARGET Estradiol 0.01% Vag Cream TriHealth Inc. marketed Estrogen receptor agonist Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Vaginal estradiol tablets Vaginal estradiol tablets Johns Hopkins University marketed Estrogen receptor agonist Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estriol Cream 0.1% Estriol Cream 0.1% Dr. August Wolff GmbH & Co. KG Arzneimittel marketed Estrogen receptor agonist Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estriol cream estriol cream Hatice Tukenmez Kurnaz marketed Estrogen receptor agonist Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estradiol valerat estradiol valerat farzaneh hojjat marketed Estrogen receptor agonist Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Estradiol (E2 0.3mg) Estradiol (E2 0.3mg) Bayer phase 3 Estrogen receptor agonist Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
estradiol (Zesteem) estradiol (Zesteem) Renovo phase 3 estrogen receptor agonist estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor agonist class)

  1. Actavis Inc. · 1 drug in this class
  2. Bayer · 1 drug in this class
  3. Dr. August Wolff GmbH & Co. KG Arzneimittel · 1 drug in this class
  4. Hatice Tukenmez Kurnaz · 1 drug in this class
  5. Johns Hopkins University · 1 drug in this class
  6. Martin Blomberg Jensen · 1 drug in this class
  7. TriHealth Inc. · 1 drug in this class
  8. farzaneh hojjat · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estradiol 0.01% Vag Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/estradiol-0-01-vag-cream. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: